Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT03922555Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inqovi in glioma (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jul 2019; status: recruiting.
02
Drugs
inqovi
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03922555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922555.